SCHEMBL875236

SCHEMBL875236

CCc1ccc(C(=O)Nc2ccc(S(=O)(=O)C(CCn3nnc4ccc(C)cc4c3=O)C(=O)O)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.45
GPR139 Q6DWJ6 1/20 0.40
RAB9A P51151 4/20 0.39
NPC1 O15118 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
HTT P42858 1/20 0.38
MMP9 P14780 2/20 0.38
CTNNB1 P35222 2/20 0.38
TCF7L2 Q9NQB0 2/20 0.38
MMP2 P08253 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL875092 0.94 GPR139 (0.44) MAPTGPR139RAB9ASMN1; SMN2CA1
SCHEMBL874946 0.91 CTNNB1 (0.43) MAPTGPR139SMN1; SMN2HTTMMP9
SCHEMBL874269 0.91 CTNNB1 (0.43) MAPTGPR139RAB9ANPC1CA1
SCHEMBL874966 0.90 GPR139 (0.49) MAPTGPR139RAB9ANPC1MMP9
SCHEMBL878193 0.89 MMP2 (0.48) GPR139SMN1; SMN2MMP9MMP2
SCHEMBL878389 0.88 CTNNB1 (0.45) GPR139RAB9ACA1CA2HTT
SCHEMBL874819 0.88 GPR139 (0.44) MAPTGPR139RAB9ASMN1; SMN2HTT
SCHEMBL875435 0.87 GPR139 (0.49) MAPTGPR139RAB9ANPC1CA1
SCHEMBL874410 0.86 HTT (0.54) GPR139RAB9ASMN1; SMN2HTTMMP9
SCHEMBL878120 0.83 MAPT (0.46) MAPTGPR139RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US claimed
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US disclosed
EP-2619185-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP disclosed
WO-2012038942-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP12, MMP10 MAPT 2663/4885GPR139 2694/4885RAB9A 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.